Rachel T. McGovern - Concepedia

Author

Rachel T. McGovern

Bristol-Myers Squibb (United States)

Also Known As

R. McGovern, R. T. MCGOVERN, Rachel McGovern, Rachel T McGovern, Rachel T. McGovern

Publications

422

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)

About

Rachel T. McGovern is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	175
2	Health Sciences	1	1	10
3	Chemical Biology	1	1	25
4	Immunology	1	1	10
5	Neuroscience	1	1	34

Rachel T. McGovern

Publications

292

Citations

H-Index

Page 1

	Year	Citations
Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial C Cohen, Leopoldo Nieto‐Cisneros, Carlos Zala, Current Medical Research and Opinion	2005	93
Molecular characterization, pharmacological properties and chromosomal localization of the human GALR2 galanin receptor Zahra Fathi, Peter M Battaglino, Lawrence G. Iben, Molecular Brain Research Molecular PharmacologyMolecular CharacterizationG Protein-coupled ReceptorMedicinePharmacological Properties	1998	83
Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y1 receptor antagonist Ildiko Antal‐Zimanyi, Marc A. Bruce, Karen L. LeBoulluec, European Journal of Pharmacology Molecular PharmacologyNeuropeptidesPharmacological CharacterizationAppetite Suppressive PropertiesAppetite Control	2008	34
Bivalent indoles exhibiting serotonergic binding affinity Karen L. LeBoulluec, Ronald J. Mattson, Cathy D. Mahle, Bioorganic & Medicinal Chemistry Letters Bivalent IndolesFunctional SelectivityMedicineMolecular SubstrateNeuropharmacology	1995	25
Temporal trends in the discontinuation of first-line antiretroviral therapy Alejandro González‐Serna, K. Chan, B. Yip, Journal of Antimicrobial Chemotherapy	2014	24
Synthesis and evaluation of 5,5-diphenylimidazolones as potent human neuropeptide Y5 receptor antagonists Kevin W. Gillman, Mendi A. Higgins, Graham S. Poindexter, Bioorganic & Medicinal Chemistry Molecular PharmacologyMedicineNeuropeptide ReceptorNeuropharmacologyPharmacotherapy	2006	23
CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology. Martin Reck, Haolan Lu, Greta Gribkoff, Journal of Clinical Oncology Squamous HistologyImmunologyImmunoeditingPathologyImmunotherapy	2012	10

Page 1